← Trials/Trial dossier/NCT05766358
EXPEND-FU
CompletedRole Of Metabolic Adaptation In Weight Regain
Role Of Metabolic Adaptation In Weight Regain: Expend Follow-Up
Lead sponsor
Asset
Tirzepatide
Subcutaneous · GLP-1 / GIP dual
Listed sites
1
Recruiting sites
—
Enrollment
27
actual
Study population
Obesity / overweight
Key I/E criterion
—
Primary endpoint
•Body weight
Footprint
Where this trial recruits
Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Investigational agents
Study populations
Who this study enrolls
Eligibility
Who can enroll
Study population text
Participants having completed the NCT04081337 study.
Inclusion criteria
Exclusion criteria
Endpoints (9)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
Weight & body composition
9 endpointsBody weight
Time frame:24 months
descriptive, improvement
Body weight
Time frame:12 months
descriptive, improvement
Body weight
Time frame:18 months
descriptive, improvement
Body fat mass (DXA)
Time frame:12 months
Total fat mass
change from baseline, improvement
Body fat mass (DXA)
Time frame:18 months
Total fat mass
change from baseline, improvement
Body fat mass (DXA)
Time frame:24 months
Total fat mass
change from baseline, improvement
Body fat free mass (DXA)
Time frame:12 months
Lean mass
change from baseline, improvement
Body fat free mass (DXA)
Time frame:18 months
Lean mass
change from baseline, improvement
Body fat free mass (DXA)
Time frame:24 months
Lean mass
change from baseline, improvement
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.